Results 211 to 220 of about 368,987 (265)

ErbB Receptor Feedback Inhibitor 1 Mutation in Biliary Tract Cancers: Turning Resistance Into Response. [PDF]

JCO Precis Oncol
Peshin S, Saj F, Kasi PM, David F, Szklaruk J, Kimana Q, Pant S, Lee SS, Knox JJ, Borad MJ, Javle M.   +10 more
europepmc   +1 more source

Sunvozertinib in EGFR Exon 20 Insertion NSCLC: Approved but Not Available - Practical Dose Selection Considerations and Real-World Access Challenges. [PDF]

Lung Cancer (Auckl)
Aldecoa KAT, Arter ZL, Ou SI, Nagasaka M.   +3 more
europepmc   +1 more source

Effect of prior anti-EGFR therapy and baseline ctDNA profiling on the efficacy of pertuzumab plus trastuzumab in HER2-amplified metastatic colorectal cancer: an integrated analysis of TRIUMPH/MyPathway. [PDF]

ESMO Open
Matsubara Y, Wakabayashi M, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, Masuishi T, Nishina T, Bando H, Misumi T, Fukui M, Matsuda S, Ikeda Y, Malato J, Schulze K, Price R, Sato A, Yoshino T, Nakamura Y.   +19 more
europepmc   +1 more source

Dacomitinib for EGFR-L858R-mutated non-small cell lung cancer following acquired resistance to third-generation EGFR-TKIs: a retrospective real-world study. [PDF]

Transl Lung Cancer Res
Wang Q, Yin X, Zhao K, Li Y, Kong L, Jiang L, Zhao H, Wang X, Li X, Chen Y, Meng X.   +10 more
europepmc   +1 more source

Investigating the Shared Mechanisms of Endocrine-Disrupting Chemicals in Urogenital Tumors. [PDF]

Biology (Basel)
Liu C, Wu S, Zhou R, Xiao S, Yang C.
europepmc   +1 more source

A Multicenter, Open‐Label, Phase 2 Trial Comparing Crizanlizumab Combined With Standard Therapy to Standard Therapy Alone on Renal Function in Patients With Sickle Cell Nephropathy (STEADFAST)

American Journal of Hematology, EarlyView.
Kenneth I. Ataga, Pablo Bartolucci, Santosh L. Saraf, Vimal K. Derebail, Adlette Inati, Jeffrey D. Lebensburger, Laurie DeBonnett, Rodolfo D. Cancado, Claire C. Sharpe   +8 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

EGFR and anti-EGFR nanobodies: review and update

Journal of Drug Targeting, 2020
Targeted therapy is one of the favourable methods used in cancer treatment. Several recombinant proteins and small-molecules used for this aim include monoclonal antibodies, antibody fragments and peptides. Nanobody (Nb) is a camelid antibody fragment that is very effective in targeted therapy.
Jafar Sharifi, Mohammad Reza Khirehgesh, Fatemeh Safari, Bahman Akbari   +3 more
openaire   +2 more sources